Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe site revision has been updated from v3.5.2 to v3.5.3, indicating a new software release. This backend update does not alter the visible study details content on the page.SummaryDifference0.0%

- Check8 days agoChange DetectedUpdated the displayed region name for the Bordeaux site from “Nouvelle-Aquitaine” to “New Aquitaine,” while retaining the same city and postal code.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2 on the page.SummaryDifference0.0%

- Check22 days agoChange DetectedAdded Padova, Italy, 35128 and removed Padua, Italy, 35128 from the list of study locations.SummaryDifference0.0%

- Check30 days agoChange DetectedAdded the term Differentiated thyroid carcinoma and a Resources section linking the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check37 days agoChange DetectedAdded Naples, Italy, 80131 as a study location and removed Napoli, Italy, 80131. The page revision was updated to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.